Hummingbird Insights LP
Contributor since: 2020
Company: Hummingbird investment group ltd
Articles
NeoGenomics: Market Punishment Continues, But Looks Justified
Cerus: Technical Support Fades, Investment Case Weakens (Technical Analysis)
AngioDynamics: Lack Of Upside Capture Remains, Continue To Hold
Pediatrix: These 5 Graphs Suggest It's A Buy
Artivion: Stopping PROACT Xa Trial Removes Long-Term Growth Driver
Smith & Nephew: Needs To Break Long-Term Downtrend, $35 Key Technical Level
Pro-Dex: Growth Trends In Earnings, Return On Investment Contracting
Establishment Labs: Flat Earnings, Return On Investment Keep Buyers At Bay
enVVeno Medical: Unique Exposure To Venous Treatment Domain
Patterson Companies: Unfairly Punished, Mispricing Opportunity Ahead
SeaSpine: Bottom Line Fundamentals Continue To Soften
DexCom: Mid-Term Growth Levers In Place Despite Lofty Multiples
Tandem Diabetes Care: Overpriced, Underdelivering
ConMed: Fairly Priced At Pre-Pandemic Market Cap
Outset Medical: Tablo Ship Hold A Key Overhang To Unlock Risk Capital
Keep Adding To STAAR Surgical Longs, Buy Thesis Remains
Agiliti: Mid-Term Growth Drivers Now Tight Following HHS, Guidance Updates
National Research Corp: Market Is Discounting These Key Factors
CareMax: Numbers Are Strong, Compelling Value On Offer
InfuSystem: Profitability, Earnings Trends Justify Valuation Discount
Privia Health: In Line For Solid FY22, Hold On Valuation
Select Medical: Adding To Position For Further Upside Capture
Inogen: Structural, Supply Chain Headwinds Remain
Integra LifeSciences: Wide Dislocation In Fundamentals Vs. Market Value
Avanos: Recent Entry To Hyaluronic Acid Market Sparks Interesting Debate
Biomerica: One To Watch Closely For The Future, But From The Sidelines For Now
Merit Medical: No Change To Hold Thesis, ROIC Still One To Watch
Mesa Laboratories: Softening Bottom Line Fundamentals, Fairly Priced
Atrion: Attractively Priced For Exposure To Defensive Healthcare
Beyond Air: Bottom Line Fundamentals Keep Buyers At Bay
Bioventus: Reiterating Buy Thesis Following Q2 Earnings
LeMaitre Vascular: Reiterate Buy Thesis Following Strong Q2 Numbers
BioSig: No Changes To Hold Thesis Following Q2 Earnings
Cutera: Shares Very Attractively Priced, Top-Line Hedged From CMS
ViewRay: Pay Fair Value For Differentiated Strengths In Niche Sector
Nevro: Niche Operator In Neuropathy, Reluctant Hold On Valuation
Axonics Stock Is A Buy Amid Current Capex Cycle
Co-Diagnostics: Hold Thesis Remains Well Intact
OraSure: Revenue Mix Continues To Present Risk
Neuronetics: Growth To Capture, But Fairly Priced